InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research report released on Sunday morning. The firm issued a sell rating on the stock.

Several other research analysts also recently commented on NSPR. Lake Street Capital initiated coverage on InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price objective on the stock. Piper Sandler restated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Price Performance

NYSE:NSPR opened at $2.71 on Friday. The company has a market capitalization of $70.69 million, a price-to-earnings ratio of -3.61 and a beta of 0.99. The business has a 50 day moving average of $2.75 and a 200 day moving average of $2.70. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.42.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The company had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same quarter in the prior year, the company earned ($0.15) EPS. As a group, sell-side analysts anticipate that InspireMD will post -0.79 EPS for the current year.

Hedge Funds Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC purchased a new position in InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned 0.74% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.